MTPA announces long-term findings from post-marketing safety study of Radicava
Analysis of Post-Marketing Safety Data Shows Consistent Findings with Safety Profile Reported in Clinical Trials of Edaravone
Analysis of Post-Marketing Safety Data Shows Consistent Findings with Safety Profile Reported in Clinical Trials of Edaravone
States were also strongly advised to strictly monitor epidemiological profile of admitted COVID patients
The over-the-counter market has long been an important segment of Glenmark’s portfolio around the world
Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
Strengthens investment in channels of the future to expand patient reach
First and only PARP inhibitor to improve invasive disease-free survival in patients
Medidata Detect and Rave CTMS Have Improved Study Execution Through Role-Based Monitoring Workflows and Clinical Data Visualization for Hundreds of Customers Across More Than 9,000 Studies
By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities
Dr. Reddy's acquired the Eton portfolio for an upfront payment of approximately $5 million in cash, plus contingent payments of up to $45 million.
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
Subscribe To Our Newsletter & Stay Updated